4521 科研薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	76,871	-899	-1.2%	-206	-0.3%	2,144	2.8%	56.57	-18.3%	赤転	赤転	-84.6%
2025/03	4Q	94,035	21,034	22.4%	21,279	22.6%	13,945	14.8%	365.42	30.5%	121.1%	113.8%	73.8%
2024/03	4Q	72,044	9,513	13.2%	9,951	13.8%	8,025	11.1%	212.67	-1.3%	18.9%	14.0%	47.5%
2023/03	4Q	72,984	7,998	11.0%	8,727	12.0%	5,440	7.5%	144.80	-4.0%	-53.1%	-50.3%	-43.0%
2022/03	4Q	76,034	17,064	22.4%	17,542	23.1%	9,549	12.6%	251.43	1.4%	-4.1%	-3.7%	-28.8%
2021/03	4Q	74,979	17,788	23.7%	18,222	24.3%	13,405	17.9%	347.37	-16.0%	-32.9%	-32.4%	-30.8%
2020/03	4Q	89,232	26,512	29.7%	26,946	30.2%	19,370	21.7%	494.89	-5.2%	7.8%	7.9%	9.0%
2019/03	4Q	94,165	24,592	26.1%	24,972	26.5%	17,775	18.9%	445.78	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	76,871	-899	-1.2%	-206	-0.3%	2,144	2.8%	56.57	-18.3%	赤転	赤転	-84.6%
2025/03	4Q	94,035	21,034	22.4%	21,279	22.6%	13,945	14.8%	365.42	30.5%	121.1%	113.8%	73.8%
2024/03	4Q	72,044	9,513	13.2%	9,951	13.8%	8,025	11.1%	212.67	-1.3%	18.9%	14.0%	47.5%
2023/03	4Q	72,984	7,998	11.0%	8,727	12.0%	5,440	7.5%	144.80	-4.0%	-53.1%	-50.3%	-43.0%
2022/03	4Q	76,034	17,064	22.4%	17,542	23.1%	9,549	12.6%	251.43	1.4%	-4.1%	-3.7%	-28.8%
2021/03	4Q	74,979	17,788	23.7%	18,222	24.3%	13,405	17.9%	347.37	-16.0%	-32.9%	-32.4%	-30.8%
2020/03	4Q	89,232	26,512	29.7%	26,946	30.2%	19,370	21.7%	494.89	-5.2%	7.8%	7.9%	9.0%
2019/03	4Q	94,165	24,592	26.1%	24,972	26.5%	17,775	18.9%	445.78	-	-	-	-